2024-08-25 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including HIV/AIDS, hepatitis B and C, oncology, and inflammation.

**1. Performance vs. S&P 500 (VOO):**

Gilead Sciences (GILD) has underperformed the S&P 500 (VOO) significantly. While VOO has generated a cumulative return of 71.75%, GILD has only managed a 10.92% return. This difference is reflected in the current relative divergence of -60.81, indicating that GILD is currently lagging behind VOO by 60.81% compared to its historical performance range. 

**2. Recent Price Movement:**

GILD is currently trading at $76.72. 
* The 5-day moving average is $75.39.
* The 20-day moving average is $75.18.
* The 60-day moving average is $70.59.
This suggests a recent upward trend in the stock price, with the price trading above its short-term moving averages. 

**3. Technical Indicators Analysis:**

* **RSI:** The RSI of 63.06 indicates that GILD is in the overbought territory, implying potential for a near-term correction.
* **PPO:** The PPO of -0.08 suggests that the momentum of the stock is slightly negative, hinting at a possible slowdown in its upward trend.
* **Delta_Previous_Relative_Divergence:** The negative value of -4.78 signifies a recent decrease in the relative divergence between GILD and VOO. This suggests that GILD's performance compared to VOO has been improving slightly. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report (2024-08-08) shows that GILD exceeded analysts' expectations, reporting an EPS of 1.29 against an expected EPS of 1.07. Revenue also exceeded expectations, reaching 6.95 billion dollars against an expected 6.75 billion dollars. These positive results might be attributed to the strong performance of GILD's HIV and HCV franchises. 

**5. Overall Analysis:**

GILD is currently experiencing a positive price movement, supported by recent strong earnings results that beat analysts' expectations. However, the stock is still lagging behind the S&P 500 in terms of cumulative return and is currently overbought according to RSI. While the relative divergence is improving, it remains negative. Investors should monitor the stock's performance in the coming months to assess whether it can sustain its recent momentum and outperform the market. 

**6. Conclusion:**

Gilead Sciences (GILD) is a profitable biopharmaceutical company with a strong market position in its core areas of focus. The company's recent earnings results were encouraging, exceeding analysts' expectations. However, the stock is currently overbought and remains behind the broader market in terms of performance. Further observation is needed to gauge the sustainability of the current price trend and its ability to outperform the market. 
